Collateral damage from cephalosporin or quinolone antibiotic therapy
被引:342
作者:
Paterson, DL
论文数: 0引用数: 0
h-index: 0
机构:
Univ Pittsburgh, Med Ctr, Div Infect Dis, Antibiot Management Program, Pittsburgh, PA 15213 USAUniv Pittsburgh, Med Ctr, Div Infect Dis, Antibiot Management Program, Pittsburgh, PA 15213 USA
Paterson, DL
[1
]
机构:
[1] Univ Pittsburgh, Med Ctr, Div Infect Dis, Antibiot Management Program, Pittsburgh, PA 15213 USA
Collateral damage" is a term used to refer to ecological adverse effects of antibiotic therapy; namely, the selection of drug-resistant organisms and the unwanted development of colonization or infection with multidrug-resistant organisms. The risk of such damage can be assessed for different antibiotic classes by a variety of epidemiologic studies. Cephalosporin use has been linked to subsequent infection with vancomycin-resistant enterococci, extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, beta-lactam-resistant Acinetobacter species, and Clostridium difficile. Quinolone use has been linked to infection with methicillin-resistant Staphylococcus aureus and with increasing quinolone resistance in gram-negative bacilli, such as Pseudomonas aeruginosa. Neither third-generation cephalosporins nor quinolones appear suitable for sustained use in hospitals as "workhorse" antibiotic therapy.
引用
收藏
页码:S341 / S345
页数:5
相关论文
共 59 条
[1]
Ariffin H, 2000, Int J Infect Dis, V4, P21, DOI 10.1016/S1201-9712(00)90061-4